Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072332 | 1.00 | KDM4E (0.36) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6071864 | 0.91 | KDM4E (0.37) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6071874 | 0.91 | KDM4E (0.37) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6071869 | 0.91 | KDM4E (0.37) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6071868 | 0.91 | KDM4E (0.37) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6072731 | 0.91 | KDM4E (0.38) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6072741 | 0.91 | KDM4E (0.38) | KDM4EGLAFFAR4GAAALDH1A1 | |
| SCHEMBL6072046 | 0.90 | KDM4E (0.41) | KDM4EGLAGAAALDH1A1 | |
| SCHEMBL6072057 | 0.90 | KDM4E (0.41) | KDM4EGLAGAAALDH1A1 | |
| SCHEMBL6072411 | 0.90 | KDM4E (0.35) | KDM4EGLAFFAR4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | claimed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | KDM4E 358/4885GLA 1944/4885FFAR4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.